Results of conservative treatment of locally advanced larynx squamous cell carcinoma using intraarterial regional polychemotherapy

The study objective is to evaluate the results of organ-preserving treatment of locally advanced larynx squamous cell carcinoma.

Materials and methods. Analysis of 28 patients with locally advanced larynx squamous cell carcinoma (stages III-IV) who underwent treatment at the N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia between 2017 and 2020 was performed. At the first stage, 2-3 courses of combined inductive polychemotherapy per the DCF scheme with 21-day interval were performed (docetaxel 60 mg/m², cisplatin 60 mg/m² intraarterially bolus with detoxication with sodium thiosulfate, 5-fluorouracil 1000 mg/m²/day as 96-hour infusion). The second stage included external beam radiotherapy (60-70 Gy, 2 Gy per day 5 days a week) as monotreatment if complete clinical response after chemotherapy was achieved or with regional administration of cisplatin (60 mg/m² once per 3 weeks) if after inductive stage full clinical response wasn»t observed.

Results. In 20 (71.5 %) patients, complete clinical response was observed after inductive treatment; in 7 (25 %) patients, partial response was observed. Tumor stabilization was detected in 1 (3.5 %) patient. Two-year overall survival was 95.8 ± 4.1 %, progression-free survival was 90.1 ± 6.8 %.

Conclusion. The proposed strategy of organ-preserving treatment of stage III-IV larynx cancer with substitution of systemic chemotherapy with regional intraarterial chemotherapy prior to radiotherapy is highly effective from the point of view of direct anti-tumor effect and recurrence-free and overall survival.

1. Nocini R., Molteni G., Mattiuzzi C., Lippi G. Updates on larynx cancer epidemiology. Chin J Cancer Res 2020;32(1):18—25. DOI: 10.21147/j.issn.1000-9604.2020.01.03;

2. Steuer C.E., El-Deiry M., Parks J.R. et al. An update on larynx cancer. CA Cancer J Clin 2017;67(1):31—50. DOI: 10.3322/caac.21386.

3. American Cancer Society. Cancer Facts and Figures 2019. Atlanta: American Cancer Society, 2019. Available online: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf

4. Kaprin A.D. The state of oncological care for the population in Russia in 2019. Moscow, 2017. 16 p. (In Russ.).

5. Kaprin A.D., Starinsky V.V. Malignant neoplasms in Russia in 2015 (morbidity and mortality). Moscow: P. A. Herzen Moscow State Medical Research Institute-branch of the Federal State Budgetary Institution “NMIRC” of the Ministry of Health of Russia, 2017 (In Russ.).

6. Ciolofan M.S., Vlaescu A.N., Mogoanta C.A. et al. Clinical, Histological and Im-munohistochemical Evaluation of Larynx Cancer. Curr Health Sci J 2017;43(4): 367-75. DOI: 10.12865/CHSJ.43.04.14.

7. Steuer C.E., El-Deiry M., Parks J.R. et al. An update on larynx cancer. CA Cancer J Clin 2017;67(1):31—50. DOI: 10.3322/caac.21386.

8. Islami F., Tramacere I., Rota M. et al. Alcohol drinking and laryngeal cancer: overall and dose-risk relation--a systematic review and meta-analysis. Oral Oncol 2010;46(11):802-10. DOI: 10.1016/j.oraloncology.2010.07.015.

9. Altieri A., Garavello W., Bosetti C. et al. Alcohol consumption and risk of laryngeal cancer. Oral Oncol 2005;41(10):956-65. DOI: 10.1016/j.oraloncology.2005.02.004.

10. Raitiola H., Pukander J., Laippala P. Glottic and Supraglottic Laryngeal Carcinoma: Differences in Epidemiology, Clinical Characteristics and Prognosis. Acta Otolaryngol 1999;119(7),847—51. DOI: 10.1080/00016489950180531.

11. Williamson A.J., Bondje S. Glottic Cancer. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2021.

12. Markou K., Christoforidou A., Karasmanis I. et al. Laryngeal cancer: epidemiological data from Northern Greece and review of the literature. Hippokratia 2013;17(4):313—8.

13. Howlader N., Noone A.M., Krapcho M. et al(eds). SEER Cancer Statistics Review, 1975-2016, National Cancer Institute, Bethesda, MD, https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission, posted to the SEER website, April 2019.

14. Sheahan P., Ganly I., Rhys-Evans P.H., Patel S.G. Tumors of the Larynx. Principles and Practice of Head and Neck Surgery and Oncology. London: Informa, 2009. 658p.

15. Badwal J.S. Total Laryngectomy for Treatment of T4 Laryngeal Cancer: Trends and Survival Outcomes. Pol Przegl Chir 2018;6;91(3):30—7. DOI: 10.5604/01.3001.0012.2307.

16. Stankovic I., Milisavljevic D., Stankovic M. et al. Survival after Salvage Total Laryngectomy: The Influence of Previous Treatment. J Nucl Med Radiat Ther 2017;8:1 DOI: 10.4172/2155-9619.1000322.

17. Babin E., Beynier D., Le Gall D., Hitier M. Psychosocial quality of life in patients after total laryngectomy. Rev Laryngol Otol Rhinol (Bord) 2009;130(1):29—34.

18. McQuellon R.P., Hurt G.J. The psychosocial impact of the diagnosis and treatment of laryngeal cancer. Otolaryngol Clin North Am 1997;30(2):231—41.

19. Bindewald J., Oeken J., Wollbrueck D. et al. Quality of life correlates after surgery for laryngeal carcinoma. Laryngoscope 2007;117(10):1770-6. DOI: 10.1097/MLG.0b013e3180caa18c.

20. Subramaniam N., Balasubramanian D., Reddy R. et al. Organ Preservation Protocols in T4 Laryngeal Cancer: a Review of the Literature. Indian J Surg Oncol 2019;10(1):149—55. DOI: 10.1007/s13193-018-0840-9.

21. Forastiere A.A., Goepfert H., Maor M. et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349(22):2091-8. DOI: 10.1056/NEJMoa031317.

22. Tang Z.X., Gong J.L., Wang Y.H. et al. Efficacy comparison between primary total laryngectomy and nonsurgical organ-preservation strategies in treatment of advanced stage laryngeal cancer: A meta-analysis. Medicine (Baltimore) 2018;97(21):e10625. DOI: 10.1097/MD.0000000000010625.

23. Forastiere A.A., Zhang Q., Weber R.S. et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 2013;31(7):845—52. DOI: 10.1200/JCO.2012.43.6097.

24. Forastiere A.A., Zhang Q., Weber R.S. et al. Long-term results of RTOG 91-11: a comparison of three non-surgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 2013;31(7):845—52. DOI: 10.1200/JCO.2012.43.6097.

25. Ghadjar P., Simcock M., Zimmermann F. et al. Predictors of severe late radiotherapy-related toxicity after hyperfrac-tionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial(SAKK 10/94). Radiother Oncol 2012;104(2):213—18. DOI: 10.1016/j.radonc.2012.05.004.

26. Machtay M., Moughan J., Trotti A. et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008; 26(21): 3582-9. DOI: 10.1200/JCO.2007.14.8841.

27. Orphanidou C., Biggs K., Johnston M.E. et al. Prophylactic feeding tubes for patients with locally advanced head-and-neck cancer undergoing combined chemotherapy and radiotherapy-systematic review and recommendations for clinical practice. Curr Oncol 2011;18(4):e191—201. DOI: 10.3747/co.v18i4.749.

28. Nguyen N.P., North D., Smith H.J. et al. Safety and effectiveness of prophylactic gastrostomy tubes for head and neck cancer patients undergoing chemora-diation. Surg Oncol 2006;15(4):199—203. DOI: 10.1016/j.suronc.2006.12.002.

29. Robbins K.T., Kumar P., Regine W.F. et al. Targeted chemoradiation for advanced head and neck cancer — analysis of 213 patients. Head Neck 2000;22(7):687—93. DOI: 10.1002/1097-0347(200010)22:7<687::aid-hed8>3.0.co;2-w.

30. Foote R.L., Kasperbauer J.L., Okuno S.H. et al. A pilot study of high-dose intraarterial cisplatin chemotherapy with concomitant accelerated radiotherapy for patients with previously untreated T4 and selected patients with T3N0-N3M0 squamous cell carcinoma of the upper aerodigestive. Cancer 2005;103(3):559—68. DOI: 10.1002/cncr.20803.

31. Rabbani A., Hinerman R.W., Schmalfuss I.M. et al. Radiotherapy and concomitant intraarterial cisplatin (RADPLAT) for advanced squamous cell carcinomas of the head and neck.Am J Clin Oncol 2007;30(3):283—6. DOI: 10.1097/01.coc.0000258118.38177.74.

32. Homma A., Sakashita T., Yoshida D. et. al. Superselective intra-arterial cisplatin infusion and concomitant radiotherapy for maxillary sinus cancer- British Journal of Cancer 2013;109(12):2980—6. DOI: 10.1038/bjc.2013.663.

33. Furusaka T., Asakawa T., Tanaka A. et al. Efficacy of multidrug superselective intraarterial chemotherapy (docetaxel, cisplatin, and 5-fluorouracil) using the Seldinger technique for tongue cancer. Acta Otolaryngol 2012;132(10):1108—14. DOI: 10.3109/00016489.2012.684702.

34. Vermorken J.B., Remenar E., van Herpen C. et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357(17):1695—704. DOI: 10.1056/NEJMoa071028.

35. Postner M.R., Hershock D.M., Blajiman C.R. et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357(17):1705—15. DOI: 10.1056/NEJMoa070956.

36. Yokoyama J. A novel laryngeal preservation therapy for advanced laryngeal cancer (T3, 4) by superselective intra-arterial chemotherapy / Yokoyama J., Furukawa M. J Jpn Bronchoesophageal Soc 2009;60:93—9.

37. Nomura K. Intra-arterial cisplatin with concomitant radiation for advanced hypopharyngeal cancer. Laryngoscope 2013;123(4):916—22. DOI: 10.1002/lary.23870.

38. Yoshizaki T., Kondo S., Wakisaka N. Concurrent Intra-arterial Chemotherapy and Radiotherapy for Advanced Laryngeal Cancer. Ann Otol Rhinol Laryngol 2009;118(3):172—8. DOI: 10.1177/000348940911800303.

39. Richard J.M., Sancho H., Lepintre Y. et al. Intra-arterial methotrexate chemotherapy and telecobalt therapy in cancer of the oral cavity and oropharynx. Cancer 1974;34(3):491—6. DOI: 10.1002/1097-0142(197409)34:3<491::aid-cncr2820340303>3.0.co;2-g.

40. Pointreau Y., Garaud P., Chapet S. et al. Randomized Trial of Induction Chemotherapy With Cisplatin and 5-Fluorouracil With or Without Docetaxel for Larynx Preservation. JNCI Journal of the National Cancer Institute 2009;101(7):498—506. DOI: 10.1093/jnci/djp007.

41. Sanders I.W., Haslet K., Correa P. Sequential TPF chemotherapy followed by concurrent chemoradiotherapy in locally advanced head and neck cancer — a retrospective analysis of toxicity and outcomes. Scott Med J 2014;59(1):50—5. DOI: 10.1177/0036933013518153.

42. Lorch J.H., Goloubeva O., Haddad R.I. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 2011;12(2):153—59. DOI: 10.1016/S1470-2045(10)70279-5.

43. Kowalski L.P. Batista M.B., Santos C.R. et al. Prognostic factors in T3, N0-1 glottic and transglottic carcinoma. A multifactorial study of 221 cases treated by surgery or radiotherapy. Arch Otolaryngol Head Neck Surg 1996;122(1):77—82. DOI: 10.1001/archotol.1996.01890130069011.

44. Lin D.J., Goodfellow M., Ong J. et al. Treatment outcomes of laryngectomy compared to non-surgical management of T3 laryngeal carcinomas: a 10-year multicentre audit of 179 patients in the northeast of England. J Laryngol Otol 20)20;134(12.):1103—7. DOI: 10.1017/S0022215120002704.

45. Vartanyan A. A., Ogorodnikova M. V. Molecular mechanisms of action of platinum preparations. Russian Biotherapeutic Journal 2004;3(1):14—9. URL: https://cyberleninka.ru/article/n/molekulyarnye-mehanizmy-deystviya-preparatov-platiny (accessed: 09.02.2021) (In Russ.).